HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chetan Lathia Selected Research

Neoplasms (Cancer)

7/2011Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
10/2010Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
7/2009Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
8/2008A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
8/2007Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
6/2007Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
9/2006Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
5/2006Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
1/2006Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
10/2005Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chetan Lathia Research Topics

Disease

12Neoplasms (Cancer)
07/2011 - 08/2002
3Melanoma (Melanoma, Malignant)
11/2011 - 06/2007
3Kidney Neoplasms (Kidney Cancer)
10/2010 - 06/2007
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2012 - 05/2007
2Hypertension (High Blood Pressure)
11/2011 - 08/2005
2Hepatocellular Carcinoma (Hepatoma)
03/2011 - 09/2006
2Renal Cell Carcinoma (Grawitz Tumor)
10/2010 - 07/2009
1Adenocarcinoma
02/2015
1Colorectal Neoplasms (Colorectal Cancer)
02/2015
1Liver Cirrhosis (Hepatic Cirrhosis)
03/2011
1Fibrosis (Cirrhosis)
03/2011
1Hyperbilirubinemia
03/2011
1Disease Progression
03/2011
1Breast Neoplasms (Breast Cancer)
08/2009
1Diarrhea
05/2007
1Neutropenia
01/2006
1Lymphopenia (Lymphocytopenia)
01/2006
1Thrombocytopenia (Thrombopenia)
01/2006
1Fatigue
01/2006
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2006
1Ovarian Neoplasms (Ovarian Cancer)
01/2006
1Agranulocytosis (Granulocytopenia)
10/2005
1Exanthema (Rash)
08/2005

Drug/Important Bio-Agent (IBA)

14Sorafenib (BAY 43-9006)FDA Link
01/2012 - 08/2005
6Biomarkers (Surrogate Marker)IBA
02/2015 - 08/2005
3Phosphotransferases (Kinase)IBA
02/2015 - 05/2006
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2010 - 08/2005
2Blood Proteins (Serum Proteins)IBA
01/2012 - 10/2010
2Lipase (Acid Lipase)FDA Link
11/2011 - 01/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2010 - 07/2009
2raf KinasesIBA
09/2006 - 08/2005
1Cell-Free Nucleic AcidsIBA
02/2015
1regorafenibIBA
02/2015
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
11/2011
1Dextromethorphan (Racemethorphan)FDA LinkGeneric
11/2011
1Omeprazole (Prilosec)FDA LinkGeneric
11/2011
1Cytochrome P-450 CYP2C19IBA
11/2011
1Cytochrome P-450 CYP3AIBA
11/2011
1Midazolam (Versed)FDA LinkGeneric
11/2011
1IsoenzymesIBA
11/2011
1Cytochrome P-450 CYP2D6 (CYP2D6)IBA
11/2011
1Growth Factor ReceptorsIBA
07/2011
1Dacarbazine (DIC)FDA LinkGeneric
07/2011
1Tissue Inhibitor of Metalloproteinase-1IBA
10/2010
1Carbonic Anhydrase IXIBA
10/2010
1Carboplatin (JM8)FDA LinkGeneric
08/2008
1Paclitaxel (Taxol)FDA LinkGeneric
08/2008
1Erlotinib Hydrochloride (CP 358,774)FDA Link
08/2007
1aldesleukin (Proleukin)FDA Link
06/2007
1Interleukin-2 (IL2)IBA
06/2007
1Alanine Transaminase (SGPT)IBA
05/2007
1Gefitinib (Iressa)FDA Link
05/2007
1thiamine triphosphorate (TTP)IBA
09/2006
1tyrosine receptor (receptor, tyrosine)IBA
09/2006
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
05/2006
1Tyrosine (L-Tyrosine)FDA Link
05/2006
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
05/2006
1GemcitabineFDA Link
01/2006
120- O- (Nalpha- (4- (3- O- methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecinIBA
10/2005
1LactonesIBA
10/2005
1GlycoconjugatesIBA
10/2005
1CamptothecinIBA
10/2005
1Mitogen-Activated Protein KinasesIBA
08/2005
1Pentostatin (Nipent)FDA LinkGeneric
08/2002

Therapy/Procedure

2Therapeutics
02/2015 - 03/2011
1Drug Therapy (Chemotherapy)
08/2009